Risk of severe COVID-19 by age group for increased risk patients not accessing antiviral treatment— Mass General Brigham, June to December 2022. by Scott Dryden-Peterson (227433)

Subjects:

Equivalent elastic modulus of the capsule under case 1 and case 3. by Hongliang Zhang (149767)

Equivalent Poisson’s ratio of the capsule under case 1 and case 3. by Hongliang Zhang (149767)

Fig 1 - by Christian Karagiannidis (64152)

Subjects:

Estimated time-lags and case ascertainment for time-delay models fit to REACT-1 using the time series of daily cases. by Oliver Eales (11495186)

Subjects:

Characteristics of vaccinated population by anti-COVID-19 vaccine brand (27 December 2020–30 September 2021). by Cristina Morciano (9397154)

Subjects:

Case #5 by Bálint Lakatos (10535348)

Case #2 by Bálint Lakatos (10535348)

Scaled, pairwise relative Weighted Interval Score (rWIS; see <i>Methods</i> for description) by location for national and state/territory/DC forecasts, averaged across all horizons... by Velma K. Lopez (18510171)

Risk of severe COVID-19 by WHO risk groups for increased risk patients not accessing antiviral treatment— Mass General Brigham, June to December 2022. by Scott Dryden-Peterson (227433)

Subjects:

Risk of severe COVID-19 by NIH prioritization tier for increased risk patients not accessing antiviral treatment— Mass General Brigham, June to December 2022. by Scott Dryden-Peterson (227433)

Subjects:

Case #4 by Bálint Lakatos (10535348)

Case #3 by Bálint Lakatos (10535348)

LOH resulting in 189R/R produces a strong decrease in drug susceptibility. by Pétra Vande Zande (17628246)

Epidemiological curve of COVID-19 cases by generated starting date, the Netherlands, 27 February –1 June 2020 (n = 1,208). by Mitch van Hensbergen (11624798)

Summary statistics of daily COVID-19 cases (per 100,000 population) in each city. by Abdul Mueed (12436636)

Subjects:

Continuous ranked probability score relative to the score of the no-interaction model against increasing forecast horizon (one to four weeks). by James D. Munday (9756105)

The numerical solution of model (1) for infected compartment vs. time with different scenarios of Phase 5 in the First Case: 1^<i>st</i> scenario, no lockdown is implemented; 2^<i>nd</i> scenario, no lockdown while <i>SD</i> increases; 3^<i>rd</i> scenario, lockdown increases; 4^<i>th</i> scenario, <i>SD</i> increases; 5^<i>th</i> scenario, lockdown decreases; 6^<i>th</i> scenario, <i>SD</i> decreases; 7^<i>th</i> scenario, lockdown and <i>SD</i> increases; 8^<i>th</i> scenario, lockdown decreases and <i>SD</i> increases; 9^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 4; 10^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 4 while <i>SD</i> increases; 13^<i>th</i> scenario, lockdown and <i>SD</i> decrease. by Sara K. Al-Harbi (12418482)

“…<p>The numerical solution of model <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0265779#pone.0265779.e002" target="_blank">(1)</a> for infected compartment vs. time with different scenarios of Phase 5 in the First Case: 1^<i>st</i> scenario, no lockdown is implemented; 2^<i>nd</i> scenario, no lockdown while <i>SD</i> increases; 3^<i>rd</i> scenario, lockdown increases; 4^<i>th</i> scenario, <i>SD</i> increases; 5^<i>th</i> scenario, lockdown decreases; 6^<i>th</i> scenario, <i>SD</i> decreases; 7^<i>th</i> scenario, lockdown and <i>SD</i> increases; 8^<i>th</i> scenario, lockdown decreases and <i>SD</i> increases; 9^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 4; 10^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 4 while <i>SD</i> increases; 13^<i>th</i> scenario, lockdown and <i>SD</i> decrease.…”

Monthly distribution of COVID-19, influenza A/B, RSV and GAS cases during Seasons I and II. by Indrė Stacevičienė (11653912)

Validation of the selected models for the prediction of death in confirmed cases of COVID-19. by Wendy Nieto-Gutierrez (6029735)

Subjects: